PDX - Breast cancer model

Breast cancer Patient-derived xenografts - PDX offer the most translational preclinical model for efficacy screening in Breast cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, breast cancer patient derived xenograft models reflect the heterogeneity and diversity of the human patient population. PDX provide stable models which more closely recapitulate the characteristics of the parental tumor than traditional xenografts – such as histo- and molecular pathology, driver mutations, and oncogenic changes – offering a more predictive alternative for preclinical drug evaluation. Click this link to see our full line up of Breast Cancer PDX Models https://models.crownbio.com/model/pdx/breast-cancer/